NASDAQ: PHXMPhaxiam Therapeutics Sa Stock
$4.52-0.33 (-6.8%)
Updated Dec 8, 2023
PHXM Price
$4.52
Fair Value Price
N/A
Market Cap
$14.85M
52 Week Low
$3.00
52 Week High
$14.00
P/E
-1.21x
P/B
0.38x
P/S
3.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.35M
Earnings
-$12.53M
Gross Margin
100%
Operating Margin
-232.3%
Profit Margin
-191%
Debt to Equity
0.79
Operating Cash Flow
-$25M
Beta
0.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PHXM Overview
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PHXM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHXM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHXM is good value based on its book value relative to its share price (0.38x), compared to the US Biotechnology industry average (5.42x)
P/B vs Industry Valuation
PHXM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PHXM due diligence checks available for Premium users.
Be the first to know about important PHXM news, forecast changes, insider trades & much more!
PHXM News
Valuation
PHXM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.21x
Industry
11.7x
Market
31.32x
PHXM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.38x
Industry
5.42x
PHXM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PHXM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PHXM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PHXM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$72.0M
Liabilities
$31.8M
Debt to equity
0.79
PHXM's short-term assets ($32.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHXM's short-term assets ($32.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHXM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PHXM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PHXM vs Biotech Stocks
Phaxiam Therapeutics Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.